EZH2 Gene

• The EZH2 Gene encodes a histone methyltransferase, a key component of the Polycomb Repressive Complex 2 (PRC2).
• Its primary role is to silence genes involved in cell differentiation and development, ensuring proper cell identity.
• Mutations or overexpression of the EZH2 Gene are frequently observed in numerous cancers, promoting uncontrolled cell growth.
• EZH2 is a significant target in cancer research for developing novel therapeutic strategies.

What is the EZH2 Gene and Its Function?

The EZH2 Gene (Enhancer of Zeste Homolog 2) is a gene that provides instructions for making a protein known as EZH2. This protein is a crucial component of the Polycomb Repressive Complex 2 (PRC2), a multiprotein complex responsible for epigenetic gene silencing. The primary EZH2 gene function involves adding methyl groups to a specific amino acid (lysine 27) on histone H3 proteins, a process called H3K27 trimethylation. This modification leads to a more compact chromatin structure, effectively “turning off” genes by making them inaccessible for transcription.

By regulating gene expression, the EZH2 protein plays a vital role in numerous biological processes, including cell proliferation, differentiation, embryonic development, and stem cell self-renewal. It ensures that cells maintain their correct identity and function by silencing genes that are not appropriate for their specific type or developmental stage. For instance, in developing tissues, EZH2 helps to suppress genes that would promote differentiation into other cell types, thereby maintaining the stem cell state or guiding cells towards their intended lineage.

EZH2 Gene Mutations and Their Role in Cancer

While the EZH2 Gene is essential for normal development and cellular function, its dysregulation is strongly implicated in the initiation and progression of various cancers. Both gain-of-function mutations and overexpression of EZH2 can lead to oncogenic effects. The EZH2 gene mutation effects often result in increased H3K27 trimethylation, which silences tumor suppressor genes and genes involved in cell differentiation, thereby promoting uncontrolled cell growth, survival, and metastatic potential.

Dysregulation of EZH2 has been identified in a wide array of human malignancies, making it a significant focus in oncology research. For example, mutations in EZH2 are commonly found in follicular lymphoma and diffuse large B-cell lymphoma, where they contribute to the aggressive nature of the disease. Overexpression of EZH2, without specific mutations, is also prevalent in many solid tumors, including:

• Prostate cancer
• Breast cancer
• Lung cancer
• Melanoma
• Glioblastoma

In these contexts, elevated EZH2 levels can drive cancer cell proliferation, inhibit apoptosis (programmed cell death), and enhance invasiveness. Consequently, the EZH2 protein has emerged as a promising therapeutic target. Extensive EZH2 gene cancer research is underway to develop inhibitors that can block its enzymatic activity, thereby reactivating silenced tumor suppressor genes and potentially slowing or reversing cancer progression. Several EZH2 inhibitors are currently being investigated in clinical trials, showing promise in specific cancer types.